Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?

References

• Kimura W, Ohtsubo K. Incidence, sites of origin, and immunohistochemical and histochemical characteristics of atypical epithelium and minute carcinoma of the papilla of Vater. Cancer 1988; 61: 1394–402
   PubMed Web of Science ®Google Scholar
• Kimura W, Futakawa N, Yamagata S, et al. Different clinicopathologic findings in two different histologic subtypes of carcinoma of papilla of Vater. Jpn J Cancer Res 1994; 85: 161–6
   PubMedGoogle Scholar
• Matsubayashi H, Watanabe H, Yamaguchi T, et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumor of papilla of Vater. Cancer 1999; 86: 596–607
   PubMed Web of Science ®Google Scholar
• Albores-Saavedra J, Henson D E, Klimstra D S. Tumors of the Extrahepatic Bile Ducts, and Ampulla of Vater. Atlas of Tumor Pathology, Third Series, Fascicle 27. Armed Forces Institute of Pathology, Washington, DC 2000; 272–80
   Google Scholar
• Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J Hepatobiliary Pancreat Surg 2004; 11: 223–31
   PubMedGoogle Scholar
• Drummond F., Putt W, Fox M. Clonning and chromosome assignment of the human CDX2 gene. Ann Hum Genet 1997; 61: 393–400
   PubMed Web of Science ®Google Scholar
• Kim Y S. Mucin glycoproteins in gastrointestinal malignancies and metastasis. Eur J Gastroenterol 1993; 5: 219–25
   Web of Science ®Google Scholar
• James R, Erler T, Kazenwadel J. Structure of the murine homebox gene cdx-2: expression in embryonic and adult intestinal epithelium. J Biol Chem 1994; 269: 15229–37
   PubMed Web of Science ®Google Scholar
• Silberg D G, Swain G P, Suh E R, Traber T G. CDx1 and CDx2 expression during intestinal development. Gastroenterology 2000; 119: 961–71
   PubMed Web of Science ®Google Scholar
• Lynch J P, Silberg D G. To differentiate of proliferate? The interaction between PI13K/PTEN and Cdx2. Gastroenterology 2002; 123: 1395–7
   PubMed Web of Science ®Google Scholar
• Suh E, Traber P G. An intestine-specific homebox gene regulates proliferation and differentiation. Mol Cell Biol 1996; 16: 619–25
   PubMed Web of Science ®Google Scholar
• De Lott L B, Morrison C, Suster S, et al. CDX2 is a useful marker intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med 2005; 129: 1100–5
   PubMed Web of Science ®Google Scholar
• Fan Z, Li J, Dong B, Huang X. Expression of CDX2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res 2005; 11: 6162–70
   PubMed Web of Science ®Google Scholar
• Werling R W, Haziji H, Bacchi C E, Gown A M. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin. An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003; 27: 303–10
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Mizoshita T, Tsukamoto T, et al. CDx2 expression in pancreatic tumors: Relationship with prognosis of invasive ductal carcinomas. Oncol Rep 2004; 12: 1239–43
   PubMed Web of Science ®Google Scholar
• Mazziotta R M, Borczuk A C, Powel C A, Mansukhani M. CDX2 immunostaining as a gastrointestinal marker. Expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol 2005; 13: 55–60
   PubMedGoogle Scholar
• Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004; 17: 1392–9
   PubMed Web of Science ®Google Scholar
• Chu P G, Schwarz R E, Lau S K, Yen Y, Weiss L M. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma. Am J Surg Pathol 2005; 29: 359–67
   PubMed Web of Science ®Google Scholar
• Ortiz-Rey J A, Alvarez C, San Miguel P, et al. Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal-type adenocarcinoma. Appl Immunohistochem Mol Morphol 2005; 13: 142–6
   PubMedGoogle Scholar
• Phillips R W, Frierson H F, Moskaluk C A. CDX2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003; 27: 1442–7
   PubMed Web of Science ®Google Scholar
• Cathro H P, Mills S E. Immunophenotypic differences between intestinal-type and low-grade papillary sinonasal adenocarcinomas. An immunohistochemical study of 22 cases utilizing CDX2 and MUC2. Am J Surg Pathol 2004; 23: 1026–32
   Web of Science ®Google Scholar
• Hong S M, Cho H, Moskaluk C A, et al. CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. Am J Clin Pathol 2005; 124: 361–70
   PubMed Web of Science ®Google Scholar
• Ho S B, Niehans G A, Lyftogt C, et al. Heterogeneity of mucin expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641–51
   PubMed Web of Science ®Google Scholar
• Lee M J, Lee H S, Kim W H, et al. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 2003; 16: 403–10
   PubMed Web of Science ®Google Scholar
• Zhou H, Schaefer N, Wolff M, Fischer H P. Carcinoma of the ampulla of Vater. Comparative and histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 2004; 28: 875–82
   PubMed Web of Science ®Google Scholar
• Yonezawa S, Nakamura A, Horinouchi M, Sato E. The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg 2002; 9: 328–41
   PubMedGoogle Scholar
• Adsay N V, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002; 15: 1087–95
   PubMed Web of Science ®Google Scholar
• Steininger H, Pfofe D A, Muller H, et al. Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005; 201: 573–7
   PubMed Web of Science ®Google Scholar
• Lord R V, Brabender J, Wickramasinghe K, et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 2005; 138: 924–31
   PubMed Web of Science ®Google Scholar
• Wennerberg A E, Nalesnik M A, Coleman W B. Hepatocyte Paraffin 1: A monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 1993; 143: 1050–4
   PubMed Web of Science ®Google Scholar
• Pang Y, von Turkovich M, Wu H, et al. The binding of thyroid transcription factor-1 and hepatocyte paraffin 1 to mitochondrial proteins in hepatocytes: a molecular and immunoelectron microscopy study. Am J Clin Pathol 2006; 125: 722–6
   PubMed Web of Science ®Google Scholar
• Lamps L W, Folpe A L. The diagnostic value of Hepatocyte Paraffin 1 antibody in differentiating hepatocellular neoplasms from nonhepatic tumors: A review. Adv Anat Pathol 2003; 10: 39–43
   PubMed Web of Science ®Google Scholar
• Lugli A, Tornillo L, Mirlacher M, et al. Hepatcyte Paraffin 1 expression in human normal and neoplastic tissues. Tissue microarray analysis on 3940 tissue samples. Am J Clin Pathol 2004; 122: 721–7
   PubMed Web of Science ®Google Scholar
• Minervini M I, Demetris A J, Lee R G, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 1997; 10: 686–92
   PubMed Web of Science ®Google Scholar
• Kumagai I, Masuda T, Sato S, Ishikawa K. Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to grade and histological pattern. Hepatol Res 2001; 20: 312–9
   PubMed Web of Science ®Google Scholar
• Chu P G, Ishigawa S, Wu E, Weiss L M. Hepatocyte antigen as a marker of hepatocellular carcinoma: An immunohistochemical comparison to carcinoembrionic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002; 26: 978–88
   PubMed Web of Science ®Google Scholar
• Villari D, Caruso R, Grosso M, et al. Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study. Pathology 2002; 34: 423–6
   PubMed Web of Science ®Google Scholar
• Kanitakis J, Chouvet B, Claudy A, Scoazec J Y. Immunoreactivity of Hepatocyte Paraffin 1 monoclonal antibody in cutaneous metastatic tumors. Am J Clin Pathol 2004; 122: 85–89
   PubMed Web of Science ®Google Scholar
• Thamboo T P, Wee A. Hep Par 1 expression in carcinoma of the cervix: implications for diagnosis and prognosis. J Clin Pathol 2004; 57: 48–53
   PubMed Web of Science ®Google Scholar
• Fan Z, van de Rijn M, Montgomery K, Rouse R V. Hep Par 1 antibody stain for the differential diagnosis of hepatocelleular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003; 16: 137–44
   PubMed Web of Science ®Google Scholar
• Ramos-Vara J A, Miller M A. Immunohistochemical characterization of canine intestinal epithelial and masenchymal tumors with a monoclonal antibody to hepatocyte paraffin 1 (Hep Par 1). Histochem J 2002; 34: 397–401
   PubMedGoogle Scholar
• Lee H S, Kim W H, Kang G H. Hepatocyte expressions in hepatocellular carcinomas, gastrointestinal neoplasms, and non-neoplastic gastrointestinal mucosa: its role as a diagnostic marker. J Korean Med Sci 2003; 18: 842–8
   PubMed Web of Science ®Google Scholar
• Chu P G, Jiang Z, Weiss L W. Hepatocyte antigen as a marker of intestinal metaplasia. Am J Surg Pathol 2003; 27: 952–9
   PubMed Web of Science ®Google Scholar
• Joo M, Kim H, Kim M K, et al. Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol 2005; 20: 1039–45
   PubMed Web of Science ®Google Scholar
• Hansel D E, Maitra A, Lin J W, et al. Expression of the caudal-type homeodomain transcription factors CDX1/2 and outcome in carcinomas of the ampulla of Vater. J Clin Oncol 2005; 23: 1811–8
   PubMed Web of Science ®Google Scholar
• Fasano M, Theise N D, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal carcinoembrionic antigen. Mod Pathol 1998; 11: 934–8
   PubMed Web of Science ®Google Scholar
• Sugiki T, Yamamoto M, Aruga A, et al. Immunohistochemical evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1. J Surg Oncol 2004; 88: 104–7
   PubMed Web of Science ®Google Scholar
• Lau S K, Prakash S, Geller S A, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002; 33: 1175–81
   PubMed Web of Science ®Google Scholar
• Morrison C, Marsh W, Jr, Flankel W L. A comparison of CD10 to pCEA, MOC31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol 2002; 15: 1279–87
   PubMed Web of Science ®Google Scholar
• Siddiqui M T, Saboorian M H, Gokaslan S T, et al. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in the fine needle aspiration samples. Cancer 2002; 96: 49–52
   PubMed Web of Science ®Google Scholar
• Kakar S, Muir T, Murphy L M, et al. Immunoreactivity of Hep Par 1 in hepatic and extrahapatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol 2003; 119: 361–6
   PubMed Web of Science ®Google Scholar